Bonn-Miller MO, Babson KA, Vujanovic AA, Feldner MT, authors. Sleep problems and PTSD Symptoms interact to predict marijuana use coping motives: a preliminary investigation. J Dual Diagn. 2010;6:111–22.
Babson KA, Boden MT, Harris AH, Stickle TR, Bonn-Miller MO, authors. Poor sleep quality as a risk factor for lapse following a cannabis quit attempt. J Subst Abuse Treat. 2013;44:438–43. [PubMed]
Brower KJ, Perron BE, authors. Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances. Med Hypotheses. 2010;74:928–33. [PubMed Central][PubMed]
Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ, authors. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119:123–9. [PubMed]
Allsop DJ, Copeland J, Norberg MM, et al., authors. Quantifying the clinical significance of cannabis withdrawal. PLoS One. 2012;7:e44864. [PubMed Central][PubMed]
Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z, authors. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat. 2008;35:362–8. [PubMed Central][PubMed]
Copersino ML, Boyd SJ, Tashkin DP, et al., authors. Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict. 2006;15:8–14. [PubMed]
Levin FR, Mariani JJ, Brooks DJ, Xie S, Murray KA, authors. Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend. 2010;106:65–8. [PubMed Central][PubMed]
Allsop DJ, Copeland J, Lintzeris N, et al., authors. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71:281–91. [PubMed]
Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM, authors. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117:38–44. [PubMed Central][PubMed]
Haney M, Hart CL, Vosburg SK, et al., authors. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 2010;211:233–44.
Bolla KI, Lesage SR, Gamaldo CE, et al., authors. Sleep disturbance in heavy marijuana users. Sleep. 2008;31:901–8. [PubMed Central][PubMed]
Bolla KI, Lesage SR, Gamaldo CE, et al., authors. Polysomnogram changes in marijuana users who report sleep disturbances during prior abstinence. Sleep Med. 2010;11:882–9. [PubMed Central][PubMed]
Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G, authors. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord. 2003;76:279–84. [PubMed]
Cui S, Bowen RC, Gu G, Hannesson DK, Yu PH, Zhang X, authors. Prevention of cannabinoid withdrawal syndrom by lithium: involvement of oxytocinergic neuronal activation. J Neurosci. 2001;21:9867–76. [PubMed]
Winstock A, Lea T, Copeland J, authors. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol (Oxf). 2009;23:84–93.
Braga R, Panaitescu A, Badescu S, Zagrean A, Zagrean L, authors. Intranasal administration of oxytocin alters sleep architechture. Biol Rhythm Res. 2014;45:69–75.
McCall WV, Blocker JN, D'Agostino R Jr.; et al., authors. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med. 2010;11:822–7. [PubMed Central][PubMed]
Billiard M, author. Lithium carbonate: effects on sleep patterns of normal and depressed subjects and its use in sleep-wake pathology. Pharmacopsychiatry. 1987;20:195–6. [PubMed]
Johnston J, Lintzeris N, Allsop DJ, et al., authors. Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology (Berl). 2014;231:4623–36.
Ellingsen P, author. Double-blind trial of triazolam 0.5 mg vs. nitrazepam 5 mg in outpatients. Acta Psychiatr Scand. 1983;67:154–8. [PubMed]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1994.
Morgenthaler T, Alessi C, Friedman L, et al., authors. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep. 2007;30:519–29. [PubMed]
Soldatos CR, Dikeos DG, Paparrigopoulos TJ, authors. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48:555–60. [PubMed]
Lovibond SH, Lovibond PF, authors. Manual for the depression anxiety and stress scales. 2nd ed. Sydney: Psychology Foundation, 1995.
Norberg MM, Mackenzie J, Copeland J, authors. Quantifying cannabis use with the Timeline Followback approach: a psychometric evaluation. Drug Alcohol Depend. 2012;121:247–52. [PubMed]
Carson DS, Bosanquet DP, Carter CS, Pournajafi-Nazarloo H, Blaszczynski A, McGregor IS, authors. Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users. Exp Clin Psychopharmacol. 2012;20:497–503. [PubMed]
Szeto A, McCabe PM, Nation DA, et al., authors. Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin. Psychosom Med. 2011;73:393–400. [PubMed Central][PubMed]
Bell ML, Fairclough DL, authors. Practical and statistical issues in missing data for longitudinal patient reported outcomes. Stat Methods Med Res. 2014;23:440–59. [PubMed]
Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G, authors. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat. 2003;13:179–90. [PubMed]
Rubin D, author. Inference and missing data. Biometrika. 1976;63:581–92.
Budney AJ, Hughes JR, authors. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19:233–8. [PubMed]
Budney AJ, Moore BA, Vandrey RG, Hughes JR, authors. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112:393–402. [PubMed]
Loewen A, Siemens A, Hanly P, authors. Sleep disruption in patients with sleep apnea and end-stage renal disease. J Clin Sleep Med. 2009;5:324–9. [PubMed Central][PubMed]
Thomas RJ, author. Sleep fragmentation and arousals from sleep-time scales, associations, and implications. Clin Neurophysiol. 2006;117:707–11. [PubMed]
Sadeh A, author. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev. 2011;15:259–67. [PubMed]
Jacobus J, Bava S, Cohen-Zion M, Mahmood O, Tapert SF, authors. Functional consequences of marijuana use in adolescents. Pharmacol Biochem Behav. 2009;92:559–65. [PubMed Central][PubMed]
Kaplan KA, McQuaid J, Primich C, Rosenlicht N, authors. An evidence-based review of insomnia treatment in early recovery. J Addict Med. 2014;8:389–94. [PubMed]
Morgan PT, Pace-Schott EF, Sahul ZH, Coric V, Stickgold R, Malison RT, authors. Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: evidence for occult insomnia. Drug Alcohol Depend. 2006;82:238–49. [PubMed]
Stores G, author. Clinical diagnosis and misdiagnosis of sleep disorders. J Neurol Neurosurg Psychiatry. 2007;78:1293–7. [PubMed Central][PubMed]
Roth T, author. Does effective management of sleep disorders reduce substance dependence? Drugs. 2009;69 Suppl 2:65–75.
Spruyt K, Gozal D, Dayyat E, Roman A, Molfese DL, authors. Sleep assessments in healthy school-aged children using actigraphy: concordance with polysomnography. J Sleep Res. 2011;20:223–32. [PubMed Central][PubMed]
Marino M, Li Y, Rueschman MN, et al., authors. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep. 2013;36:1747–55. [PubMed Central][PubMed]